Article info
Poster Presentations
Psoriatic arthritis
FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis
Citation
FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis
Publication history
- First published June 15, 2017.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions